Risk for all-cause mortality increased in adults with history of smoking with normal spirometry <\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Oct. 3, 2023 (HealthDay News) — For adults with a history of smoking and normal spirometry, suspected bronchiectasis is associated with an increased risk for all-cause mortality, according to a study published online Oct. 3 in the Annals of Internal Medicine<\/em>.<\/p>\n Alejandro A. Diaz, M.D., M.P.H., from Brigham and Women’s Hospital in Boston, and colleagues examined the association between suspected bronchiectasis, ascertained using artificial intelligence-based measurements of an airway-to-artery ratio greater than 1, and mortality in adults with normal spirometry, preserved ratio impaired spirometry (PRISm), and obstructive spirometry in a prospective observational cohort. A total of 7,662 non-Hispanic Black or White adults aged 45 to 80 years with 10 or more pack-years of smoking history were included in the Genetic Epidemiology of Chronic Obstructive Pulmonary Disease (COPDGene) cohort and were stratified into normal spirometry (3,277), PRISm (986), and obstructive spirometry (3,399).<\/p>\n Overall, 17.6 percent of the participants had suspected bronchiectasis. The researchers found that 2,095 participants (27.3 percent) died during a median follow-up of 11 years. Higher 10-year mortality was seen for those with suspected bronchiectasis versus those without suspected bronchiectasis (differences in mortality probability [95 percent confidence intervals], 0.15 [0.09 to 0.21], 0.07 [\u00e2\u0088\u00920.003 to 0.15], and 0.06 [0.03 to 0.09] for normal spirometry, PRISm, and obstructive spirometry, respectively). The differences were attenuated in the normal spirometry group when only computed tomography was used to identify bronchiectasis (difference in mortality probability [95 percent confidence interval], 0.04 [\u00e2\u0088\u00920.001 to 0.08]).<\/p>\n “We found that suspected bronchiectasis is associated with higher all-cause mortality,” the authors write.<\/strong><\/p>\n The COPDGene project was funded by the COPD Foundation through an industry advisory board.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n